ReviewProtein & cell2021
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy.
Review in Protein & cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 1 synthesis or guideline pooled it, 250 citations in OpenAlex.
- A Matching Strategy To Guide Donor Selection for Ulcerative Colitis in Fecal Microbiota Transplantation: Meta-Analysis and Analytic Hierarchy Process.Microbiology spectrum · 2023Pooled it
- Fecal microbiota transplantation restores gut microbiota diversity in children with active Crohn's disease: a prospective trial.Journal of translational medicine · 2025Trial
- The Effectiveness of Patient Training in Inflammatory Bowel Disease Knowledge via Instagram: Randomized Controlled Trial.Journal of medical Internet research · 2022Trial
- Rethinking probiotics: breaking theGut microbes · 2026Review
- Arctic Fox-DerivedLife (Basel, Switzerland) · 2026Article
- Characteristics of the Tongue Coating Microbiome and Its Subtype Differences in Patients with Inflammatory Bowel Disease.Microorganisms · 2026Article
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Mesenteric adipose tissue: from protective gatekeeper to driver of inflammatory bowel disease.Immunometabolism (Cobham, Surrey) · 2026Review
- Enteric nervous system and inflammatory bowel disease.Gastroenterology report · 2026Review
- Nanozymes in Therapeutic Prospects and Challenges for Autoimmune Diseases.International journal of nanomedicine · 2026Review
- Ardisiacrispin B, a natural triterpenoid saponins, suppresses dextran sulfate sodium-induced inflammatory bowel disease by rebalancing the gut microbiota and Th17/Treg of mice.Inflammopharmacology · 2026Article
- Article
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Effects ofFrontiers in microbiology · 2026Article
- Comparative analysis of the microbiota in gingival crevicular fluid from peri-implantitis and periodontitis using 16 S ribosomal RNA gene amplicon sequencing: a cross-sectional study.BMC oral health · 2025Article
- Modulating the gut-bladder axis: fecal transplantation protects antibiotic-treated mice from E. coli cystitis via the Ahr/Prg4 pathway.Microbiome · 2025Article
- Faecalibacterium prausnitzii Ameliorates DSS-Induced Colitis via Modulating Bile Acid Metabolism and Regulating FXR Signaling.Digestive diseases and sciences · 2025Article
- Gut Microbial Signatures Associated With Clinical Remission in Inflammatory Bowel Disease Treated With Biologics: A Comprehensive Multi-Cohort Analysis.United European gastroenterology journal · 2025Article
- The Role of the human microbiome in neurodegenerative diseases: A Perspective.Current genetics · 2025Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) has become a global disease with accelerating incidence worldwide in the 21st century while its accurate etiology remains unclear. In the past decade, gut microbiota dysbiosis has consistently been associated with IBD. Although many IBD-associated dysbiosis have not been proven to be a cause or an effect of IBD, it is often hypothesized that at least some of alteration in microbiome is protective or causative. In this article, we selectively reviewed the hypothesis supported by both association studies in human and pathogenesis studies in biological models. Specifically, we reviewed the potential protective bacterial pathways and species against IBD, as well as the potential causative bacterial pathways and species of IBD. We also reviewed the potential roles of some members of mycobiome and virome in IBD. Lastly, we covered the current status of therapeutic approaches targeting microbiome, which is a promising strategy to alleviate and cure this inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.